Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsDeborah Doroshow, MD, PhD
Assistant Professor AdjunctAbout
Copy Link
Titles
Assistant Professor Adjunct
Academic Affiliate in the History of Medicine
Biography
Deborah Doroshow is Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Adjunct Assistant Professor of the History of Medicine at the Yale University School of Medicine.
She graduated from Harvard College in 2004 with a B.A. in History and Science, where she wrote a senior thesis entitled "The Injection of Insulin Into American Psychiatry," which explored the history of insulin coma therapy for schizophrenia. It was awarded the Thomas Temple Hoopes Award for outstanding senior thesis, and a portion of it was subsequently published in the Journal of the History of Medicine and Allied Sciences.
She earned her Ph.D. in History with distinction (concentration in the History of Science and Medicine) from Yale University in December 2012, winning the Edwin W. Small prize for outstanding dissertation in American History and the Pressman Career Development Award from the American Association of the History of Medicine. Her book, Emotionally Disturbed: A History of Caring for America's Troubled Children, was published by the University of Chicago Press in 2019.
Additional historical work has included a study of bedwetting alarms and parenting practices in mid-twentieth century America (Isis, 2010) and a history of laws mandating premarital syphilis testing (Social History of Medicine, 2019). She is an active member of the American Association for the History of Medicine and enjoys mentoring clinician-historians in training.
Deborah earned her M.D. from Harvard Medical School in 2013. She completed her internship and residency in internal medicine at the Yale University School of Medicine in 2015 and her fellowship in hematology and oncology, also at Yale, in 2019. At Mount Sinai, she treats adults with lung cancer as well as adults with a variety of solid tumors as part of the Early Phase Trials Unit, where her work focuses on the DNA damage response.
Appointments
History of Medicine
Assistant Professor AdjunctPrimary
Other Departments & Organizations
Education & Training
- Resident
- Yale University School of Medicine (2015)
- MD
- Harvard Medical School (2013)
- PhD
- Yale University, History (2012)
- AB
- Harvard College, History and Science (2004)
Research
Copy Link
Overview
Medical Research Interests
ORCID
0000-0002-2221-9818
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Patricia LoRusso, DO
Joseph Paul Eder, MD
Michael Cecchini, MD
Elizabeth Horn Prsic, MD
Erin Hofstatter, MD
Jeffrey Sklar, MD, PhD
History of Medicine
Lung Neoplasms
Publications
2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial
Doroshow D, Shapiro G, Do K, Keedy V, Mahdi H, Sohal D, Hafez N, LoRusso P, Cecchini M, Sklar J, Mortimer P, Glover C, Moses J, Jürgensmeier J, Eder J. Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial. Cancer 2026, 132: e70332. PMID: 41808580, DOI: 10.1002/cncr.70332.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDNA DamageFemaleHumansIndolesMaleMiddle AgedMolecular Targeted TherapyMorpholinesMutationNeoplasmsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsPyrimidinesPyrrolesRecombinational DNA RepairSulfonamidesConceptsPoly(adenosine diphosphate ribose) polymeraseDNA damage response mutationsHomologous recombination repair defectsOlaparib combinationMedian durationDNA damage responseTargeted therapyMedian duration of benefitPI3K-Akt pathway alterationsClinical benefit ratePI3K/AKT pathway mutationsResponse Evaluation CriteriaOvarian serous cancerHigh‑grade ovarian serous cancerNext-generation sequencing resultsRepair defectsOlaparib monotherapyStable diseaseDuration of benefitSerous cancerPartial responseEvaluation CriteriaARID1A mutationsBenefit rateInhibitor olaparibCOVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium
Brown A, Hsu C, Mohsin A, Prescott L, Beeghly A, Ruiz-Garcia E, Vilar-Compte D, García-Gordillo J, Hwang C, Hijaz M, Buekers T, Singh S, Wise-Draper T, Ferrara E, McKay R, Ajmera A, Mariano M, Bhatt P, Nagaraj G, Puc M, Cosin J, Bashir B, Russell K, Halabi S, McManus H, Accordino M, Mavromatis B, Joshi M, Polimera H, Del Prete S, Rose S, Subbiah S, Faller B, Mansoor A, Eid M, Mishra S, O'Cearbhaill R, Crispens M, Shyr Y, Warner J, Halmos B, Verma A, Gartrell B, Ohri N, Sica R, Stockerl-Goldstein K, Butt O, Fiala M, Henderson J, Monahan R, Zhou A, Hallmeyer S, Bohachek P, Mundt D, Pandravada S, Patel M, Streckfuss M, Tadesse E, Thompson M, Revankar S, Peters M, Bindal P, Patel J, Piper-Vallillo A, Warner J, Arvanitis P, Egan P, Farmakiotis D, Khan H, Klein E, Mishra S, Mohsin A, Olszewski A, Vieira K, Del Prete S, Bar M, Gulati A, Lo K, Rose S, Stratton J, Weinstein P, Garcia J, Routy B, Fu P, Shouse G, Hoppenot C, Li A, Choueiri T, Bakouny Z, Connors J, Demetri G, Florez (Duma) N, Freeman D, Giordano A, Labaki C, Morgans A, Nohria A, Saliby R, Schmidt A, Van Allen E, Xu W, Zon R, El Zarif T, Halabi S, Dzimitrowicz H, Zhang T, Lyman G, Graber J, Grivas P, Hawley J, Loggers E, Lynch R, Nakasone E, Schweizer M, Tachiki L, Vinayak S, Wagner M, Yeh A, Gatson N, Dansoa Y, Makary M, Manikowski J, Vadakara J, Yossef K, Goyal S, Huynh-Le M, Rosenstein L, Yu P, Clement J, Daher A, Dailey M, Elias R, Jayaraj A, Hsu E, Menendez A, Serrano O, Hwang C, Gadgeel S, Tejwani S, Accordino M, Bhutani D, Hershman D, Ingham M, Bernicker E, Deeken J, Shafer D, Ruíz-García E, de-la-Rosa-Martinez D, Ramirez A, Vilar-Compte D, Lewis M, Rhodes T, Gill D, Low C, Mashru S, Mansoor A, Hayes-Lattin B, Cohen A, McWeeney S, Nemecek E, Williamson S, Lewis G, Smith S, Nagaraj G, Akhtari M, Castillo D, Reeves M, Berg S, Knox N, O'Connor T, Wehbe F, Altman J, Gurley M, Mulcahy M, Durbin E, Kulkarni A, Nelson H, Sachs Z, Rosovsky R, Reynolds K, Bardia A, Boland G, Fu J, Gainor J, Zubiri L, Halfdanarson T, Bekaii-Saab T, Desai A, Riaz I, Shah S, Smith K, Williams C, Shah D, Bonnen M, Mahadevan D, Ramirez A, Salazar M, Shah P, Bouganim N, Elkrief A, Panasci J, Vinh D, Nanchal R, Singh H, Riely G, Philip J, Faller B, McKay R, Ajmera A, Brouha S, Choi S, Hsiao A, Kligerman S, Nonato T, Reid E, Weissmann L, Bhatt P, Jani C, Mariano M, Thomson C, Blau S, Jhawar S, Addison D, Chen J, Gatti-Mays M, Palmer J, Stover D, Wall S, Williams N, Joshi M, Polimera H, Pomerantz L, Rovito M, Griffiths E, Advani P, Puzanov I, Jabbour S, Misdary C, Shah M, Batist G, Cook E, Dutra M, Ferrario C, Miller W, Bashir B, McNair C, Mahmood S, Mico V, Rivera A, Shah S, Cabebe E, Glover M, Jha A, Khaki A, Schapira L, Tsu-Yu Wu J, Subbiah S, Flora D, Kloecker G, Logan B, Mandapakala C, Russell K, DeCardenas K, Stith B, Edwin N, Smits M, Chism D, Owenby S, Doroshow D, Galsky M, Fazio A, Huber K, Sueyoshi M, Gulati S, Riess J, Patel K, Koshkin V, Borno H, Kwon D, Small E, Zhang S, Rubinstein S, Wood W, Andermann T, Jensen C, Wise-Draper T, Ahmad S, Grover P, Gulati S, Kharofa J, Latif T, Marcum M, Sohal D, Zamulko O, Bowles D, Geiger C, Markham M, Russ A, Saker H, Acoba J, Rho Y, Nguyen R, Feldman L, Gantt G, Hoskins K, Liu L, Khan M, Pasquinelli M, Schwartz C, Venepalli N, Wulff-Burchfield E, Kasi A, Rock C, Friese C, Fecher L, Boldt A, Yoon J, Mavromatis B, Bijjula R, Zaman Q, Reid S, Brown A, Cheng A, Croessmann S, Davis E, Enriquez K, Gillaspie E, Hausrath D, Johnson D, Li X, Slosky D, Solorzano C, Sun T, Tucker M, Wang L, Puc M, Carducci T, Goldsmith K, Van Loon S, Song Q, Topaloglu U, Moore J, Peddi P, Rosen L, McCollough B, Bilen M, Castellano C, Ravindranathan D, Hafez N, Herbst R, LoRusso P, Lustberg M, Masters T, Stratton C. COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium. JCO Oncology Advances 2026 DOI: 10.1200/oa-25-00191.Peer-Reviewed Original ResearchAltmetricConceptsGynecologic cancer patientsCOVID-19 severityOdds ratioCancer statusAssociated with severitySARS-CoV-2 infectionNon-Hispanic black raceCOVID-19 outcomesNon-Hispanic whitesSARS-CoV-2Multivariate modelInternational COVID-19Cancer patientsMortality related to infectionIntensive care unit admittanceCancer Consortium registryFactors associated with COVID-19 severitySevere COVID-19 outcomesCancer ConsortiumVulvar/vaginal cancerConclusions PatientsCancer characteristicsConsortium registryCOVID-19Black raceTrastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02).
Jung K, Oh D, Doroshow D, Artamonova E, Mammatas L, Wysocki P, Su P, Moiseyenko V, Penkov K, Stroyakovskiy D, Bartolome J, Siena S, Anoka C, Scott M, Michelini F, Puvvada S, Makker V. Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02). Journal Of Clinical Oncology 2026, 44: 734-734. DOI: 10.1200/jco.2026.44.7_suppl.734.Peer-Reviewed Original ResearchCitationsConceptsProgression-free survivalBladder cancer cohortInvestigator-assessedT-DXdBladder cancerObjective responseSubgroup analysisCancer cohortOverall survivalEfficacy outcomesAnalysis of efficacy outcomesClinically meaningful antitumor activityMedian progression-free survivalClinically meaningful activityInvestigator-assessed ORRAnti-PD-L1Advanced bladder cancerAdvanced/metastatic solid tumorsPhase 2 studyHER2-expressing tumorsIHC test resultsCentralized testingMedian DORMedian OSPretreated patientsEvolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022)
de la Fuente R, Karol A, Markus A, Argulian A, Omori R, Fujiwara Y, Joshi H, Doroshow D, Galsky M. Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022). JCO Global Oncology 2026, 12: e2500411. PMID: 41719503, DOI: 10.1200/go-25-00411.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsPhase III oncology trialsOncology trialsCross-sectional analysisCancer typesPhase III trialsStatistically significant increaseHormone therapyIII trialsOncology clinical trialsTargeted therapyTreatment modalitiesClinical trialsAnticancer therapyCancer burdenTherapyHispanic ethnicityPhase III activityControl groupCancerTherapeutic classesSignificant increaseTrialsIII activityTherapy classesUnder-reporting
2025
Who Wins? Professional Identity and the American Association for the History of Medicine's Early Career Scholar Awards
Barr J, Doroshow D, Olszewski T, Ehrenberger K. Who Wins? Professional Identity and the American Association for the History of Medicine's Early Career Scholar Awards. Journal Of The History Of Medicine And Allied Sciences 2025, 81: 111-120. PMID: 41251538, DOI: 10.1093/jhmas/jraf018.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsReal-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy
Nieva J, Wang X, Doroshow D, Servidio L, Cooper M, Lau Y, Karia P, Robichaux J. Real-World Outcomes and Subsequent Treatment Patterns in Patients with Advanced Non-Small Cell Lung Cancer and Atypical EGFR Mutations Receiving First-Line Osimertinib Monotherapy. Oncology And Therapy 2025, 14: 225-240. PMID: 41206837, PMCID: PMC12992757, DOI: 10.1007/s40487-025-00395-7.Peer-Reviewed Original ResearchAltmetricConceptsEpidermal growth factor receptor geneNon-small cell lung cancerAdvanced non-small cell lung cancerAtypical EGFR mutationsEpidermal growth factor receptor gene mutationsFirst-line osimertinibEGFR mutationsCell lung cancerOverall survivalTreatment patternsStage IIIB-IV non-small cell lung cancerLung cancerFollow-upGroup ADe novo T790MGrowth factor receptor geneCompound EGFR mutationsProgression-free survivalMedian Follow-UpFirst-line treatmentOsimertinib combinationOsimertinib monotherapyMethodsMedical recordsMutation subgroupsT790M1308 Disease-free survival with neoadjuvant cemiplimab +/- stereotactic body radiation in resectable hepatocellular carcinoma
Feng D, Crowley F, Hapanowicz O, Venturini N, Lucas N, Wu K, Wilk J, Cuevas J, Fitzgerald L, Fazilov G, Myint Z, Sadek N, Chin T, Noel C, Devraj V, Fu W, Ahn S, Hamon P, Hennequin C, Fiel M, Ward S, Brody R, Taouli B, Bane O, Kim E, Garcia-Reyes K, Buckstein M, Gunasekaran G, Tabrizian P, Doroshow D, Zhao Q, Sun D, Kaul M, Brennan L, Thanigaimani P, Miller E, Uldrick T, Lowy I, Schwartz M, Merad M, Marron T. 1308 Disease-free survival with neoadjuvant cemiplimab +/- stereotactic body radiation in resectable hepatocellular carcinoma. 2025, a1543-a1543. DOI: 10.1136/jitc-2025-sitc2025.1308.Peer-Reviewed Original ResearchP3.12.39 Long-Term Overall Survival in Advanced EGFRm NSCLC Treated With 1L Osimertinib: Results From the US, Japan, Germany and China
Nieva J, Karia P, Chander P, Cooper M, Doroshow D, Tech S, Eberhardt W, Griesinger F, Muto M. P3.12.39 Long-Term Overall Survival in Advanced EGFRm NSCLC Treated With 1L Osimertinib: Results From the US, Japan, Germany and China. Journal Of Thoracic Oncology 2025, 20: s482-s483. DOI: 10.1016/j.jtho.2025.09.901.Peer-Reviewed Original ResearchConceptsDocumentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials
Karol A, Paredes R, Argulian A, Joshi H, Weintraub L, Oguntuyo K, Miller J, Fujiwara Y, Doroshow D, Galsky M. Documentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials. Cancer 2025, 131: e70106. PMID: 41004397, DOI: 10.1002/cncr.70106.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsClinical trialsCancer clinical trialsPatient withdrawalRetention strategiesMedian proportionWithdrawal of patientsProportion of patientsCross-sectional studyProportion of withdrawalsTreatment toxicityPrimary outcomeAnticancer therapySecondary outcomesTrial qualityPatientsEfficacy estimatesPatient-initiatedTrial protocolTrialsWithdrawalDocumentation practicesStudy validityCancerTrial integrityPrevalenceEvaluating palliative care needs of early-phase clinical trial patients.
Crowley F, Zeng L, Hobensack M, Lehrman S, Afezolli D, Kelly L, Wey W, Chen J, Austin V, Easton E, Pagala A, Wu K, Lucas N, Wilk J, Marron T, Smith C, Gelfman L, Doroshow D. Evaluating palliative care needs of early-phase clinical trial patients. Journal Of Clinical Oncology 2025, 43: 12086-12086. DOI: 10.1200/jco.2025.43.16_suppl.12086.Peer-Reviewed Original ResearchConceptsPalliative careEnd-of-lifeEarly phase clinical trialsOutpatient PCReferral systemPalliative care needsSpecialty palliative careCancer type distributionPC servicesCare needsRetrospective cohort studyEvaluate demographic characteristicsPrevalent symptomsRate of constipationPC guidelinesPhysical discomfortCohort studyIncrease accessFisher's exact testPhase clinical trialsClinical trial patientsDemographic characteristicsMann-Whitney U testChi-squareCategorical variables
Academic Achievements & Community Involvement
Copy Link
Get In Touch
Copy Link